Immune Checkpoint Targeted Peptide Selection

Immune checkpoints refer to a series of molecules expressed on immune cells, regulating the degree of immune activation. They play an essential role in preventing the occurrence of autoimmunity. At Creative Biolabs, we are proud of offering immune checkpoint targeted peptide selection services to accelerate your immune checkpoint drug development projects.

About Immune Checkpoints

B7 family is a type of immune checkpoint family including co-inhibitory and co-stimulatory molecules. B7 family members, such as BTN family members, offer excellent opportunities to modulate immune response therapeutically in treating different diseases.

B7-H4 is a co-inhibitory molecule on APC (blue) and interacts with its unknown receptor (receptor X) on T cells (green) to deliver negative signaling during T cell activation. Fig.1 B7-H4 is a co-inhibitory molecule on APC (blue) and interacts with its unknown receptor (receptor X) on T cells (green) to deliver negative signaling during T cell activation. (Yanxia, 2015)

BTNs as Co-Inhibitory Molecules

Scientists demonstrated the co-inhibitory role of mouse BTNL2 in T cell immunity. In vitro studies showed that BTNL1-immunoglobulin (Ig) fusion protein suppressed low-concentration anti-cluster differentiation (CD)3-induced T cell activation and interleukin 2 (IL2) production by cell-cycle arrest.

BTNs as Co-Stimulatory Molecules

In a study, scientists found that the administration of BTNL8-immunoglobulin (Ig) enhanced anti-CD3-stimulated human CD4+ T cell proliferation and cytokine production, such as IFN-gamma (IFN-γ), tumor necrosis factor-alpha (TNFα), interleukin 8 (IL8), and interleukin 10 (IL-10). Earlier studies in cancer patients suggested that high BTN3A2 messenger RNA (mRNA) expression was associated with a good prognosis related to disease-free and overall survival in a cohort of 55 epithelial ovarian cancer (EOC) patients.

Immune Checkpoint Targeted Peptide Selection Services

Creative Biolabs provides a comprehensive range of customized, high-quality services in immune checkpoint targeted peptide development to advance your programs. If you want to know more information, please directly contact us.

Reference

  1. Yanxia, G.; Wang, A. Y. Novel Immune Check-Point Regulators in Tolerance Maintenance. Frontiers in Immunology. 2015, 6(6): 421.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.


  • Immune Checkpoint Targeted Peptide Design